Overall, fewer local, regional, and distant recurrences were observed with osimertinib, which led to its recommendation as a standard-of-care for patients with EGFR-mutated stage IB-III resected NSCLC [40]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.